Uncategorized

Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection | Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods | Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients | Effectiveness of Bivalent Boosters against Severe Omicron Infection |
Prevalence and Clinical Outcomes of Respiratory Syncytial Virus versus Influenza in Adults | Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US |
Association of culturable-virus detection and household transmission of SARS-CoV-2 – California and Tennessee, 2020–2022 | Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients

Codetections of Other Respiratory Viruses Among Children Hospitalized With COVID-19 |
Early and Increased Influenza Activity Among Children — Tennessee |
SARS-CoV-2 variant-related abnormalities detected by prenatal MRI | COVID-19 vaccines versus pediatric hospitalization |
Persistent COVID-19 Symptoms at 6 Months After Onset | Effects of Dexamethasone Use on Viral Clearance Among Patients with COVID-19: A Multicenter Cohort Study |
Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases |
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant

Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study | Effectiveness of the Bivalent mRNA Vaccine in Preventing Severe COVID-19 Outcomes: An Observational Cohort Study | 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection | Increasing Ventilation Reduces Sars-Cov-2 Airborne Transmission In Schools | Use of Carbon Dioxide Monitoring to Assess Ventilation at a National Infectious Diseases Conference

Virological characteristics of the SARS-CoV-2 XBB variant | SARS-CoV-2 infection and persistence in the human body | Long-term cardiovascular outcomes of COVID-19 | Heart-disease risk soars | Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants | Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines |
Time to negative PCR conversion among high-risk patients | The Fc-effector function of COVID-19 convalescent plasma | Infectiousness of SARS-CoV-2 breakthrough infections and reinfections

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron | Structural brain changes in post-acute COVID-19 patients | Persistent post–COVID-19 smell loss | Persistent symptoms and sequelae after SARS-CoV-2 infection | VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 | Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System | Molnupiravir plus usual care versus usual care alone as early treatment for adults | Higher dose corticosteroids in hospitalized COVID-19 patients | FDA approves Roche’s Actemra (tocilizumab) for the treatment of COVID-19 | Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine | Canine real-time detection of SARS-CoV-2 infections | Clinical Validation of a Novel T-Cell Receptor | Modelling the adjustment of COVID-19 response | Two masks can be worse than one: N95 respirator failure caused by an overlying face mask | Airflow Patterns in Double-Occupancy Patient Rooms | The epidemiology of long COVID in US adults

Immunological dysfunction persists for 8 months |
Clinical Features and Burden of Post-Acute Sequelae of SARS-CoV-2 Infection |
Demonstration of stable clusters of symptoms | Longitudinal Analysis of T cells in COVID-19 |
Reconsideration of anti-nucleocapsid IgG antibody | Early Estimates of Bivalent mRNA Vaccine |
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated
Hospitalization | Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations |
COVID-19 Convalescent Plasma Outpatient Therapy | Bacterial Co-infection and Empirical Antibiotic Therapy in Patients |
Similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples |
Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics | The WHO estimates of excess mortality associated with the COVID-19 pandemic |
Impact of SARS-CoV-2 variants on inpatient clinical outcome | Association of Time to Surgery After COVID-19 Infection

Impact of community masking on COVID-19 | Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks | What is the place in therapy for nirmatrelvir/ritonavir? | Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection or Vaccination in Pregnancy | Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations | Acute and postacute sequelae associated with SARS-CoV-2 reinfection